Kaken Pharmaceutical Co., Ltd. resolved to absorb its consolidated subsidiary ARTham Therapeutics through a merger. The effective date is scheduled for 2026-12-31. After the merger, Kaken Pharmaceutical Co., Ltd. will be the surviving company and ARTham will be the dissolved company. No share allocation will occur. The impact going forward is expected to be minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4521","jir_company_name":"Kaken Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4521-20261109-03.pdf","jir_short_summary":"Kaken Pharmaceutical Co., Ltd. resolved to absorb its consolidated subsidiary ARTham Therapeutics through a merger. The effective date is scheduled for 2026-12-31. After the merger, Kaken Pharmaceutical Co., Ltd. will be the surviving company and ARTham will be the dissolved company. No share allocation will occur. The impact going forward is expected to be minor.","jir_summary":"### Overview of the Merger\nKaken Pharmaceutical Co., Ltd. resolved at a board meeting to effect an absorption-type merger with its consolidated subsidiary, ARTham Therapeutics Co., Ltd. The effective date is scheduled for 2026-12-31, with Kaken Pharmaceutical Co., Ltd. as the surviving company and ARTham as the dissolved company. No share allocation will occur for either party, and there will be no special consideration provided for ARTham's stock acquisition rights.\n\n### Future Impact and Schedule\nThis merger is with a consolidated subsidiary of Kaken Pharmaceutical Co., Ltd., and the impact on consolidated results is expected to be minor. The resolution and contract signing date is 2026-11-09, and the effective date is scheduled for 2026-12-31.","jir_financial_highlights":"Net Sales: 76,871 (Year-over-Year Unknown)\nOperating Income: -899 (Year-over-Year Unknown)\nOrdinary Income: -206 (Year-over-Year Unknown)\nNet Income Attributable to Owners of Parent: 2,144 (Year-over-Year Unknown)\nNumber of Issued Shares: 44,139,730 (Compared to Immediate Prior Period Unknown)","jir_category":"","jir_hashtags":"#KakenPharmaceutical_AbsorptionMerger","jir_key_figures":"Number of Issued Shares: 44,139,730 shares\nNet Sales: 76,871 million yen\nNet Income Attributable to Owners of Parent: 2,144 million yen","jir_meta_title":"Kaken Pharmaceutical Co., Ltd. Resolves Absorption Merger of Consolidated Subsidiary\uff5cEffective 2026-12-31 (Scheduled)","jir_meta_description":"Kaken Pharmaceutical Co., Ltd. resolved to absorb consolidated subsidiary ARTham Therapeutics. Key points: effective date, surviving and dissolved companies, absence of share allocation, and expected minor impact.","jir_og_title":"Kaken Pharmaceutical Resolves Absorption Merger of Consolidated Subsidiary","jir_og_description":"Kaken Pharmaceutical Co., Ltd. will absorb ARTham Therapeutics. The effective date is scheduled for 2026-12-31. The impact is expected to be minor and no share allocation will occur.","jir_og_image_url":"\/assets\/og\/company-corporate_restructuring.jpg","jir_chart_data_collection":"[]","ir_related_company":9082,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-145539","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n